Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00096122 · BASELINE

Baseline characteristics

Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia · Source last updated 2014-05-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      95
    units
    Participants
groups
  1. description
    Cytarabine 1.5 g/m\^2 and Idarubicin 12 mg/m\^2 intravenous (IV) continuously on days 1-3 (or 1-4), with Oral Tipifarnib 200/300 twice daily on days 1-21, repeats every 21 days.
    id
    BG000
    title
    Idarubicin, Cytarabine + Tipifarnib
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          17
          upper Limit
          61
          value
          50
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          53
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          42
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          95
      title
      United States
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      95
    units
    Participants
groups
  1. description
    Cytarabine 1.5 g/m\^2 and Idarubicin 12 mg/m\^2 intravenous (IV) continuously on days 1-3 (or 1-4), with Oral Tipifarnib 200/300 twice daily on days 1-21, repeats every 21 days.
    id
    BG000
    title
    Idarubicin, Cytarabine + Tipifarnib
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          17
          upper Limit
          61
          value
          50
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          53
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          42
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          95
      title
      United States
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice